Takeda Pharmaceuticals Korea seeks DPP-4 market through ‘Nesina’

Published: 2014-01-22 06:56:00

Updated: 2014-01-22 06:56:00

(Yakup Shinmoon)

On Jan 17, Takeda Pharmaceuticals Korea held a large-scale symposium and press conference to announce the launch of type 2 diabetes treatment 'Nesina tablet' (ingredient: alogliptin benzoate).

Nesina tablet is a DPP-4 inhibitor for the treatment of type 2 diabetes. Takeda insisted that Nesina tablet is only agent in the same family in the domestic market that has proved...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.